GLP-1 drugs like Ozempic and Wegovy have rapidly moved from niche diabetes treatments to blockbuster weight loss injections, reshaping how doctors and patients think about obesity. As prescriptions climb, a new wave of research is surfacing side effects that are not only serious, but in some cases strange enough to catch even seasoned clinicians off guard. The promise of dramatic weight loss now sits alongside emerging questions about how these medications affect the gut, the brain, and even how medical scans are interpreted.
Rather than a single red flag, the picture that is coming into focus is a mosaic of risks, from severe gastrointestinal problems to rare vision loss and unusual imaging complications. I am seeing a shift from breathless enthusiasm to a more sober calculation of trade-offs, as large datasets and detailed case reports reveal that the story of GLP-1 drugs is more complicated than a simple miracle shot.
What GLP-1 drugs actually do inside the body
To understand why new side effects keep surfacing, it helps to start with how these medications work. GLP-1 agonists mimic a hormone that slows stomach emptying, boosts insulin release, and dampens appetite, which is why drugs such as Ozempic and Wegovy can drive significant weight loss and better blood sugar control. In a massive analysis of nearly 2,000,000 people, researchers used an analysis of health records to map how these effects play out in the real world, and the scale of that dataset is now shaping the safety conversation.
That kind of population-level work is starting to reveal patterns that smaller clinical trials could easily miss, including signals that some complications cluster in people on GLP-1 therapy. The same research that highlights benefits is also surfacing new risks, which is why regulators and clinicians are revisiting assumptions about how aggressively to prescribe these drugs and for how long.
The “Common Side Effects” that are not so minor
Patients are usually warned that nausea, diarrhea, and constipation are part of the deal with GLP-1 therapy, but those boilerplate cautions can obscure how disruptive these symptoms become in everyday life. Educational materials on Ozempic emphasize that the most common problems are nausea, vomiting, diarrhea and constipation, and that list can sound routine until someone is missing work, skipping social events, or avoiding travel because their stomach is in revolt.
Clinics that counsel patients on weight loss now routinely walk through a checklist of Common Side Effects, including stomach pain, nausea, vomiting, and heartburn, to set expectations before the first injection. I find that framing matters here: what looks like a tolerable trade-off on a consent form can feel very different when a person is dealing with daily cramps, reflux, or unpredictable bowel habits while trying to hold down a job or care for a family.
From “GI upset” to severe stomach injuries
Behind the bland phrase “GI side effects” lies a spectrum that runs from mild queasiness to life-altering injury. Reporting on people taking Ozempic and similar drugs for weight loss has linked these medications to serious gastrointestinal problems, including cases of severe pain and suspected obstruction, as clinicians describe a growing list of serious GI symptoms that go far beyond a rough first week. The “honeymoon period” of easy weight loss can end abruptly when someone lands in an emergency department with unrelenting vomiting or abdominal distension.
Legal and medical analyses now warn that Ozempic and Wegovy may cause more than discomfort, flagging that Ozempic and Wegovy May Cause Severe Stomach Injuries including intestinal blockages and even deep vein thrombosis in some patients. When I talk to gastroenterologists, they describe a new pattern of patients arriving with slowed gut motility or suspected gastroparesis after starting GLP-1 therapy, a reminder that a drug designed to keep food in the stomach longer can, in rare cases, tip into dangerous territory.
“Unexpected GLP-1 Side Effects” that blindsided regulators
As prescriptions have exploded, a second wave of complaints has started to show up in the fine print of drug labels and in the FDA’s own files. Commentators tracking post-approval data note that it can take the FDA decades to fully map out bad reactions, and that “Unexpected GLP-1 Side Effects with Ozempic, Wegovy and MANY Other Drugs” are often buried in sections labeled “Postmarketing Experience.” That is where scattered case reports of unusual reactions, from odd skin changes to unexpected neurological complaints, can quietly accumulate until a pattern becomes too obvious to ignore.
For patients, the phrase “Unexpected GLP, Side Effects, Ozempic, Wegovy and MANY Other Drugs” is more than a mouthful, it is a warning that the safety profile of these medications is still a moving target. I see a growing tension between the urgency to treat obesity and the reality that some harms will only surface after millions of injections, which is why careful reporting of new symptoms and rigorous follow up matter as much as the initial prescription.
The “unusual” imaging problem doctors did not see coming
One of the strangest developments involves how GLP-1 drugs can interfere with medical scans. Researchers in the UK have described an unusual side effect in which delayed stomach emptying leaves food in the gut during imaging, creating confusing pictures that can mimic disease or hide real problems. The study’s principal author described “changed patterns” on scans that are increasingly common, yet poorly understood by clinicians who are not thinking about GLP-1 drugs when they read an image.
Experts now advise that people on Ozempic, Wegovy, or Mounjaro may need tailored instructions before certain tests to avoid possible interference in scan interpretation, a practical fix that only emerged after radiologists started comparing notes. I find it striking that a drug designed to act on the gut is now forcing a rethink of imaging protocols, a reminder that “unusual” does not always mean rare when a medication is used at population scale.
New “bizarre” and cosmetic complaints, from jowls to cavities
Alongside the serious complications, a parallel conversation has emerged around side effects that are medically mild but psychologically potent. Reports on “The most bizarre side effects of GLP-1 weight loss drugs” describe everything from “Ozempic feet” to a runny nose, with patients swapping stories about sagging jowls, sulfurous burps, and dry mouth that leaves them reaching for flavored water enhancers to improve hydration. One account notes that GLP drugs have been linked to dry mouth and cavities, a small but real price for a slimmer waistline.
Earlier this year, another report highlighted an Unusual new side effect of drugs like Ozempic that appears to be on the rise, adding to a growing list of annoyances that can make long term use harder to tolerate. I hear from dermatologists and dentists who are now asking about Ozempic when they see sudden facial volume loss or a spike in cavities, illustrating how a metabolic drug is quietly reshaping cosmetic and dental practice as well as endocrinology.
The “annoying” cold-like effect and feeling under the weather
Not every emerging issue is dramatic enough to land someone in the hospital, but even low grade problems can chip away at quality of life. New research suggests that Drugs like Ozempic are linked to an “annoying” side effect that can leave people feeling as if they are constantly coming down with something, even when they are not actually sick. In that study, medications such as Ozempic and We were used to lower blood sugar and support weight management, yet some participants reported lingering malaise that felt like a never ending mild cold.
For someone already juggling nausea or constipation, adding a chronic “under the weather” sensation can be the tipping point that leads them to stop injections altogether. I see this as a reminder that adherence is not just about life threatening risks, it is also about whether people can tolerate the day to day grind of side effects that do not show up on lab tests but still shape how they move through the world.
Long term risks: pancreatitis, gallbladder trouble, kidneys and mood
Beyond the immediate discomforts, clinicians are increasingly focused on what happens after years on these drugs. Detailed safety reviews emphasize that Key long term concerns include pancreatitis, gallbladder problems, kidney issues, and possible thyroid tumors, even though these complications are described as Rare but serious. For patients, the message is that Ozempic is not a cosmetic quick fix, it is a powerful metabolic intervention that demands the same respect as any other chronic therapy.
At the same time, regulators in Europe and North America are scrutinizing potential links between GLP-1 drugs and mental health. New warnings have been issued as drugs like Ozempic are examined for possible connections to mood changes and suicidal thoughts, with one review noting that the risk of suicidal thoughts and behaviour is being evaluated in the context of semaglutide use and suicidal thoughts. Hollywood has helped propel these drugs into the spotlight, but the emerging mood data is a reminder that brain chemistry can be just as affected as body weight.
Rare but devastating outcomes: blindness, clots and cancer fears
Some of the most alarming reports involve rare events that are devastating when they occur. A growing number of patients claim that popular diabetes and weight loss drugs like Ozempic can cause sudden blindness linked to a condition called nonarteritic anterior ischemic optic neuropathy, a rare but very serious side effect that some say they were never warned about. These cases are still being investigated, yet they have already prompted lawsuits and calls for clearer counseling about visual symptoms.
Concerns about blood clots and intestinal blockages have also surfaced in legal filings that describe deep vein thrombosis and severe obstruction in people using Ozempic and Wegovy, reinforcing the warnings about Ozempic and Wegovy negative effects. On the cancer front, some patients have asked bluntly whether Ozempic causes tumors, prompting detailed explanations that, Thankfully, the above medical complications are rare among Ozempic patients and that Both Novo Nordisk and Eli Lilly and Compan have pointed to existing data suggesting no clear causal link. Even so, the fear itself is reshaping conversations in exam rooms, as people weigh small but frightening possibilities against the very real dangers of uncontrolled obesity and diabetes.
Telemedicine, fast prescriptions and the “danger zone”
The way people are getting these drugs is also part of the safety story. Case reports describe scenarios in which individuals with obesity and hypertension received prescriptions for tirzepatide through a telemedicine app, with limited in person evaluation and little follow up on emerging symptoms. In one detailed Case, the combination of remote prescribing and aggressive dose escalation created what authors called a “highway to the danger zone,” as red flags that might have been obvious in a clinic were missed in a quick video visit.
GLP-1 agonists represent a powerful tool for weight loss in some patients, but the telehealth boom has made it easier than ever to start injections without the kind of baseline workup or ongoing monitoring that complex drugs usually require. I see this as a structural side effect of the digital health era: when a medication is marketed heavily on social media and delivered through an app, the guardrails that traditionally protect patients can erode, leaving individuals to navigate serious risks with little more than a PDF of side effects and a customer support email.
More from MorningOverview